Partner Content Partner Content Spotlight on Key Sessions You Cannot Miss at Ophthalmic Drug... Are you aware the ophthalmic market is expected to reach $21 billion by the year 2022?
News Neurogene falls again on Rett gene therapy side effects Neurogene has halted patient enrolment in the high-dose arm of its trial of Rett syndrome gene therapy, sparking another run on its shares.
Digital Sponsored Decoding physician prescribing behaviour: A data-driven jour... Identifying high-volume prescribers and engaging with key opinion leaders (KOLs) in a target therapeutic area can be a challenge.